Location History:
- Seattle, WA (US) (2004 - 2009)
- Spring, TX (US) (2001 - 2010)
Company Filing History:
Years Active: 2001-2010
Title: Capucine Thwin: Pioneering Innovations in Adenoviral Vector Production
Introduction
Capucine Thwin is an accomplished inventor based in Seattle, WA, known for her significant contributions to the field of virology and gene therapy. With a total of six patents to her name, Thwin has been instrumental in developing methods that enhance the production and purification of adenoviral vectors, crucial for various therapeutic applications.
Latest Patents
Thwin’s latest patents focus on improving the yields of viral vectors when grown in cell culture systems. One notable invention reveals the advantages of employing low-medium perfusion rates in attached cell culture systems for adenovirus production. Furthermore, her research indicates that producing Ad-p53 with cells in serum-free conditions, particularly in serum-free suspension culture, boosts yield. A significant aspect of her methods involves the use of detergent lysis, which, combined with other innovations, allows for a streamlined purification process through a single chromatography step. This approach results in purified virus of comparable quality to that achieved through more traditional methods like double CsCl banding using ultracentrifuge, showcasing her commitment to advancing biotechnological methods.
Career Highlights
Capucine Thwin has worked with prominent companies in the biotechnology field, such as Introgen Therapeutics Inc. and Crucell Holland B.V. Her experience in these organizations has contributed significantly to her depth of knowledge and expertise in viral vector production, allowing her to develop groundbreaking technologies in her area of work.
Collaborations
Throughout her career, Thwin has collaborated with talented professionals, including Shuyuan Zhang and Zheng Wu. These partnerships have fostered a creative environment that has led to innovative solutions and advancements in adenoviral vector production methodologies.
Conclusion
Capucine Thwin continues to shape the landscape of gene therapy through her inventive approaches to adenoviral vector production. Her patents not only enhance the efficiency of production but also pave the way for future advancements in biotechnology, demonstrating her role as a key figure in the ongoing evolution of this critical field.